These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 6226333)

  • 1. Clinical aspects of the arachidonic acid--thromboxane pathway.
    Mitchell JR
    Br Med Bull; 1983 Jul; 39(3):289-95. PubMed ID: 6226333
    [No Abstract]   [Full Text] [Related]  

  • 2. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade, combined in one molecule.
    De Clerck F; Beetens J; de Chaffoy de Courcelles D; Vercammen E; Freyne E; Janssen PA
    Prog Clin Biol Res; 1989; 301():567-72. PubMed ID: 2529556
    [No Abstract]   [Full Text] [Related]  

  • 3. 7-Oxabicyclo[2.2.1]heptane analogs as modulators of the thromboxane A2 and prostacyclin receptors.
    Sprague PW; Heikes JE; Harris DN; Greenberg R
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():337-43. PubMed ID: 6303073
    [No Abstract]   [Full Text] [Related]  

  • 4. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of BM-573 [N-terbutyl-N'-[2-(4'-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism.
    Ghuysen A; Lambermont B; Dogné JM; Kolh P; Tchana-Sato V; Morimont P; Magis D; Hanson J; Segers P; D'Orio V
    J Pharmacol Exp Ther; 2004 Sep; 310(3):964-72. PubMed ID: 15121765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prostacyclin--thromboxane A2 balance: pathophysiological and therapeutic implications.
    Bunting S; Moncada S; Vane JR
    Br Med Bull; 1983 Jul; 39(3):271-6. PubMed ID: 6354352
    [No Abstract]   [Full Text] [Related]  

  • 7. [Stenocardia. Thromboxane A2 and prostacyclin].
    Panchenko EP
    Kardiologiia; 1986 Jul; 26(7):109-16. PubMed ID: 3093749
    [No Abstract]   [Full Text] [Related]  

  • 8. Exchange of cyclooxygenase dependent metabolites between vessel wall and platelets in arterial thrombosis.
    Bourgain RH; Andries R; Decuyper K; Braquet P
    Thromb Res; 1988 May; 50(3):401-8. PubMed ID: 3134741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspirin as an antithrombotic medication.
    Marcus AJ
    N Engl J Med; 1983 Dec; 309(24):1515-7. PubMed ID: 6358887
    [No Abstract]   [Full Text] [Related]  

  • 10. Biology and therapeutic potential of prostacyclin.
    Moncada S
    Stroke; 1983; 14(2):157-68. PubMed ID: 6301111
    [No Abstract]   [Full Text] [Related]  

  • 11. Acetyl glycerylphosphorylcholine aggregates human platelets through two distinct pathways, both dependent on arachidonic acid metabolism.
    Macconi D; Morzenti G; Livio M; Morelli C; Cassina G; Remuzzi G
    Lab Invest; 1985 Feb; 52(2):159-68. PubMed ID: 3155816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myocardial infarction and the arachidonic acid system in the coronary vessels.
    Wennmalm A
    Clin Physiol; 1985 Aug; 5(4):311-4. PubMed ID: 3930132
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of the infusion of OKY-046, a thromboxane A2 synthase inhibitor, on urinary metabolites of prostacyclin and thromboxane A2 in healthy human subjects.
    Morio H; Hirai A; Terano T; Tamura Y; Yoshida S
    Thromb Haemost; 1993 Mar; 69(3):276-81. PubMed ID: 8470052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R 68 070: thromboxane A2 synthetase inhibition and thromboxane A2/prostaglandin endoperoxide receptor blockade combined in one molecule--II. Pharmacological effects in vivo and ex vivo.
    De Clerck F; Beetens J; Van de Water A; Vercammen E; Janssen PA
    Thromb Haemost; 1989 Feb; 61(1):43-9. PubMed ID: 2526385
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostaglandin endoperoxides and thromboxane A2 in thrombus formation in the hamster cheek pouch in vivo.
    Lewis GP; Smith JR
    Prostaglandins; 1984 Jul; 28(1):29-41. PubMed ID: 6435186
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological studies on OKY-1581: a selective thromboxane synthetase inhibitor.
    Hiraku S; Wakitani K; Katsube N; Kawasaki A; Tsuboshima M; Naito J; Ujiie A; Komatsu H; Iizuka K
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():241-4. PubMed ID: 6221530
    [No Abstract]   [Full Text] [Related]  

  • 18. Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981.
    Vane JR
    J Endocrinol; 1982 Nov; 95(2):3P-43P. PubMed ID: 6816886
    [No Abstract]   [Full Text] [Related]  

  • 19. Prostacyclin, thromboxane A2 interactions in haemostasis and thrombosis.
    Moncada S; Amezcua JL
    Haemostasis; 1979; 8(3-5):252-65. PubMed ID: 389758
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of proaggregatory and antiaggregatory prostaglandins in hemostasis. Studies with combined thromboxane synthase inhibition and thromboxane receptor antagonism.
    Gresele P; Arnout J; Deckmyn H; Huybrechts E; Pieters G; Vermylen J
    J Clin Invest; 1987 Nov; 80(5):1435-45. PubMed ID: 2960694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.